Geron Stock Forecast, Price & News

-0.01 (-0.70 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume7.89 million shs
Average Volume4.93 million shs
Market Capitalization$452.04 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

Geron logo

About Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.10 out of 5 stars

Medical Sector

1189th out of 1,349 stocks

Pharmaceutical Preparations Industry

581st out of 663 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Geron (NASDAQ:GERN) Frequently Asked Questions

Is Geron a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Geron stock.
View analyst ratings for Geron
or view top-rated stocks.

What stocks does MarketBeat like better than Geron?

Wall Street analysts have given Geron a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Geron wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Geron

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its earnings results on Sunday, August, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.09). The biopharmaceutical company earned $0.11 million during the quarter, compared to the consensus estimate of $0.08 million. Geron had a negative trailing twelve-month return on equity of 49.12% and a negative net margin of 25,083.58%. During the same period in the previous year, the firm earned ($0.06) earnings per share.
View Geron's earnings history

How has Geron's stock been impacted by Coronavirus (COVID-19)?

Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GERN stock has increased by 36.9% and is now trading at $1.41.
View which stocks have been most impacted by COVID-19

Who are Geron's key executives?

Geron's management team includes the following people:
  • John A. Scarlett, Chairman, President & Chief Executive Officer
  • Andrew J. Grethlein, Chief Operating Officer & Executive Vice President
  • Olivia K. Bloom, Chief Financial Officer, Treasurer & Executive VP
  • Aleksandra Rizo, Chief Medical Officer & Executive Vice President
  • Melissa A. Kelly Behrs, Chief Business Officer & Executive Vice President

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron CEO John A. Scarlett on John A. Scarlett has an approval rating of 82% among Geron's employees.

Who are some of Geron's key competitors?

What other stocks do shareholders of Geron own?

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.95%), Vanguard Group Inc. (4.92%), State Street Corp (4.27%), Geode Capital Management LLC (1.63%), Northern Trust Corp (0.99%) and Charles Schwab Investment Management Inc. (0.68%).
View institutional ownership trends for Geron

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Vanguard Group Inc., Morgan Stanley, Morgan Stanley, Millennium Management LLC, Rafferty Asset Management LLC, and Citigroup Inc..
View insider buying and selling activity for Geron
or view top insider-selling stocks.

Which major investors are buying Geron stock?

GERN stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Alliancebernstein L.P., Geode Capital Management LLC, Group One Trading L.P., Susquehanna International Group LLP, Citadel Advisors LLC, Northern Trust Corp, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Geron
or or view top insider-buying stocks.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.41.

How much money does Geron make?

Geron has a market capitalization of $452.04 million and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-75,620,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

How many employees does Geron have?

Geron employs 54 workers across the globe.

What is Geron's official website?

The official website for Geron is

Where are Geron's headquarters?

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at (650) 473-7700 or via email at [email protected].

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.